Dr Yongchuan Gu


Dr Gu obtained BPharmSci in Medicinal Chemistry in 1993 and MSc in Pharmacology in 2002. He was invited to University of Otago as a visiting Research Fellow in 2002 to carry out preclinical development of a mitochondria-targeted antioxidant at School of Pharmacy. He gained experience on GLP operation / documentation at ZenithTechnology Ltd, a NZ-based bioanalytical & pharmacokinetic specialty CRO, where he acted as a Senior Scientist in charge of method development / validations for a variety of drugs. He conferred his PhD from University of Auckland in 2010 and finished postdoc training in Auckland Cancer Society Research Centre where he was responsible for preclinical development for different drug discovery programs targeting tumour hypoxia. His current research interest is developing targeted proteomics technology as a powerful tool to probe potential biomarkers of HAPs with the goal of identifying patients that will be responsive to the therapy. He was recognised with receipt of the 2013 Keith & Meida Hepburn Young Scientist of the Year Award by the Cancer Society Auckland for his contribution to anti-cancer drug development in NZ.

Teaching | Current

Drugs and Society (P111G)
PostGrad course -Pharmaceutical Quality Assurance (P752)


Li Family Cancer Research Fellowship (2016)
AAHA Collaborative Research Grant (2015)
AMRF project grant (2014)
HRC Programme (2014)
Marsden Fund (2013)
Keith & Meida Hepburn Young Scientist of the Year (2013)
NZ-China Scientist Exchange Programme (2013)
Genesis Oncology Research Grant (2011)
Technology for Industry Fellowships (2006)

Committees/Professional groups/Services

American Association for Cancer Research; American Society for Pharmacology and Experimental Therapeutics; American Association of Pharmaceutical Scientists; Auckland Cancer Research Network; Maurice Wilkins Centre

Selected publications and creative works (Research Outputs)

  • Svirskis, D., Behera, S., Naidoo, N., Beachman, J., Raina, T., Zhou, Y., ... Gu, Y. (2018). Stability of vincristine sulfate, doxorubicin hydrochloride and etoposide phosphate admixtures in polyisoprene elastomeric pump supporting transition of the EPOCH regimen to outpatient care. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners10.1177/1078155218764285
    Other University of Auckland co-authors: Darren Svirskis
  • Bonnet, M., Hong, C. R., Wong, W. W., Liew, L. P., Shome, A., Wang, J., ... Anderson, R. F. (2018). Next-generation hypoxic cell radiosensitizers: Nitroimidazole alkylsulfonamides. Journal of Medicinal Chemistry, 61 (3), 1241-1254. 10.1021/acs.jmedchem.7b01678
    Other University of Auckland co-authors: Michael Hay, Lydia Liew, Way Wong, Bob Anderson, Stephen Jamieson, Kevin Hicks, Frederik Pruijn, Ralph Stevenson, Avik Shome
  • Gu, Y., Chang, T. T.-A., Wang, J., Jaiswal, J. K., Edwards, D., Downes, N. J., ... Hickey, A. J. (2017). Reductive metabolism influences the toxicity and pharmacokinetics of the hypoxia-targeted benzotriazine di-oxide anticancer agent sn30000 in mice. Frontiers in Pharmacology, 8, 1-16. 10.3389/fphar.2017.00531
    Other University of Auckland co-authors: Tony Hickey, Jagdish Jaiswal, Frederik Pruijn, Michael Hay, William Wilson, Kevin Hicks
  • Gu, Y., Deng, K.-C., Liyanage, S., Pruijn, F., & Wilson, W. (2016). Targeted proteomic profiling of enzymes that activate the prodrug PR-104A in human leukaemias. Paper presented at 15th Human Proteome Orgnisation World Congress, Taipei, Taiwan. 18 September - 22 September 2016. 15th Human Proteome Orgnisation World Congress Abstract Book.
    Other University of Auckland co-authors: Frederik Pruijn, William Wilson
  • Cao, J., Wang, Y., Dong, R., Lin, G., Zhang, N., Wang, J., ... Ying, M. (2015). Hypoxia-Induced WSB1 Promotes the Metastatic Potential of Osteosarcoma Cells. Cancer research, 75 (22), 4839-4851. 10.1158/0008-5472.can-15-0711
  • Hunter, F. W., Young, R. J., Shalev, Z., Vellanki, R. N., Wang, J., Gu, Y., ... Goldstein, D. P. (2015). Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs. Cancer research, 75 (19), 4211-4223. 10.1158/0008-5472.can-15-1107
    Other University of Auckland co-authors: Francis Hunter, William Wilson
  • Konopleva, M., Thall, P. F., Yi, C. A., Borthakur, G., Coveler, A., Bueso-Ramos, C., ... Ravandi, F. (2015). Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. Haematologica, 100 (7), 927-934. 10.3324/haematol.2014.118455
    Other University of Auckland co-authors: William Wilson
  • Sheng, R., Li, S., Lin, G., Shangguan, S., Gu, Y., Qiu, N., ... Hu, Y. (2015). Novel potent HIF-1 inhibitors for the prevention of tumor metastasis: discovery and optimization of 3-aryl-5-indazole-1,2,4-oxadiazole derivatives. RSC Adv, 5 (100), 81817-81830. 10.1039/C5RA15191K

Contact details

Primary location

M&HS BUILDING 504 - Bldg 504
Level B, Room B01A
New Zealand

Social links